Down Syndrome Market Insight, Epidemiology and Market Forecast, 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Down Syndrome – Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Down Syndrome (DS) – Market Insights, Epidemiology, and Market Forecast – 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology and the market trends of Down syndrome (DS) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Down syndrome (DS) market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted Down syndrome market Size from 2017 to 2030, segmented by seven major markets. The report also covers current Down syndrome (DS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Country-wise Down Syndrome (DS) Epidemiology

The epidemiology segment also provides the Down syndrome (DS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed prevalent population of Down syndrome (DS) in 7MM countries was estimated to be 699,750 cases in 2017.

Down syndrome (DS) Drug Chapters

The drug chapter segment of the Down syndrome (DS) report encloses the detailed analysis of Down syndrome marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Down syndrome (DS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Down syndrome (DS) Emerging Drugs

ANVS-401 (Annovis Bio)

Annovis Bio is developing ANVS-401 as a combination therapy approach to inhibit the translation of multiple neurotoxic proteins such as APP/A? (Read more…), tau/phospho-tau, and ?-synuclein. The ANVS-401 may improve the axonal transport, increase synaptic transmission, prevent inflammation, and restore cascade events by reducing APP, tau, and Alpha-synuclein levels and preserving the health of nerve cells. The company is planning to obtain human data for AD in Down syndrome than in the regular AD population. Henceforth, it plans to conduct Phase III pivotal study in AD-DS rather than in AD.

Down syndrome (DS) Market Outlook

The Down syndrome (DS) market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Down syndrome (DS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Down syndrome (DS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The Down syndrome (DS) market in 7MM is expected to change in the study period 2017-2030.

The current market of Down syndrome is dominated by the use of supportive therapies depending on the manifestations such as anti-anxiety medications, anticonvulsants, antidepressants, anti-hypertension medications, antipsychotic medications, antispasmodics, cholesterol-lowering medications, cholinesterase inhibitors, GERD-related medications (e.g., proton pump inhibitors), hormones (other than thyroid-related hormones and others.

Key Findings

This section includes a glimpse of the Down syndrome (DS) market in 7MM. The market size of Down syndrome in the seven major markets was found to be USD 662.9 million in 2017.

Down syndrome (DS) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Down syndrome (DS) market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Down Syndrome (DS) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Down syndrome (DS) key players involved in developing targeted therapeutics.

Some of the major players and their rug candidates expected to get launched during the forecast period (2020-2030) include Annovis Bio (ANVS-401), AC Immune (ACI-24), Alzheon (ALZ-801), Balance Therapeutics (BTD-001), Aelis Farma (AEF0217), and others.

Pipeline Development Activities

The report covers the detailed information of collaborations, mergers and acquisitions, licensing, and patent details for Down syndrome (DS) emerging therapies.

Key Topics Covered:

1. Key Insights

2. Down syndrome: Market Overview at a Glance

2.1. Market Share (%) Distribution of Down syndrome in 2017

2.2. Market Share (%) Distribution of Down syndrome in 2030

3. Executive summary

4. Organizations

5. Disease Overview: Down syndrome

5.1. Introduction

5.2. Symptoms

5.3. Types of Down syndrome

5.4. Risk factors for Down syndrome

5.5. Genetic Basis of Down syndrome

5.5.1. Gene expression variation

5.6. Etiopathogenesis

5.6.1. Phenotypic Variability of Down syndrome

5.6.2. Metabolic Imbalance in Down syndrome

5.7. Clinical Conditions Associated with Down syndrome

5.8. Diagnosis of Down syndrome

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Diagnosed Prevalent Population of Down syndrome in 7MM

7. 7 MM-Epidemiology of Down syndrome

7.1. Assumptions and Rationale

7.2. United States

7.3. Total Diagnosed Prevalent Cases of Down syndrome in the US

7.4. Gender-specific cases of Down syndrome in the US

7.5. Type-specific cases of Down syndrome in the US

7.6. Age-specific cases of Down syndrome in the US

7.7. Diagnosed cases of Down syndrome by Clinical Manifestations in the US

7.8. Germany

7.9. France

7.10. Italy

7.11. Spain

7.12. The UK

7.13. Japan

8. Current Treatment Practices

8.1. Management Guidelines

8.2. American College of Obstetricians and Gynecologists

8.3. Health Care Guidelines for People with Down syndrome: European Down syndrome Association

9. Unmet needs

10. Emerging Therapies

10.1. Key cross Analysis

10.2. ACI-24: AC Immune

10.2.1. Drug Description

10.2.2. Other Developmental Activities

10.2.3. Clinical Development

10.2.4. Safety and Efficacy

10.2.5. Product Profile

10.3. ANVS-401: Annovis Bio

10.4. ALZ-801: Alzheon

10.5. ELND005: OPKO Health, Inc.

10.6. AEF0217: Aelis Farma

11. Down syndrome: Seven Major Market Analysis

11.1. Key Findings

11.2. Market Size of Down syndrome in 7MM

11.3. Market outlook

12. Market Drivers

13. Market Barriers

14. Market Access and Reimbursement

15. SWOT Analysis

16. Case studies

16.1. Neurodevelopmental Progress for Male Child with Down syndrome, Nystagmus, Myopia and Severe Digestive Issues with Pica

16.2. Jeffery: A toddler with Down syndrome

16.3. Alzheimer’s disease in Down syndrome: A Neuropsychological Case Study

17. KOL views

18. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/rjceee

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900